<DOC>
	<DOCNO>NCT02842424</DOCNO>
	<brief_summary>Peripheral artery disease ( PAD ) manifestation atherosclerosis produce progressive narrow occlusion artery supply low extremity . The common clinical manifestation PAD claudication , i.e. , severe functional limitation identify gait dysfunction walking-induced leg muscle pain relieve rest . The standard therapy claudication include medication cilostazol pentoxifylline , supervise exercise therapy operative revascularization . Recent data demonstrate 24 week treatment angiotensin-converting enzyme ( ACE ) inhibitor Ramipril produce improvement walk performance patient claudication high cilostazol pentoxifylline similar produce supervised exercise therapy operative revascularization . The mechanisms Ramipril therapy produce impressive improvement functional capacity claudicating patient remain unknown . The Investigators hypothesize treatment claudicating PAD patient Ramipril improve walk performance quality life improve myopathy gastrocnemius . Improved myopathy consequence reduce oxidative damage , reduce TGF-β1 production vascular smooth muscle cell reduce collagen deposition affect gastrocnemius .</brief_summary>
	<brief_title>Ramipril Treatment Claudication</brief_title>
	<detailed_description>This interventional study PAD patient exhibit claudication . The purpose study determine potential mechanism Ramipril vastly improve walk performance patient . The study achieve specific aim : Specific Aim # 1 : Test hypothesis Ramipril-mediated improvement walk parameter among patient PAD correlate improvement morphometrics biochemistry myofibers gastrocnemius impaired limb . Specific Aim # 2 : Test hypothesis Ramipril-mediated improvement walk parameter patient PAD correlate reduce fibrotic event small vessel microvasculature , association reduce generalized collagen deposition improve tissue oxygenation , gastrocnemius impair limb . Specific Aim # 3 : Using adult human arterial smooth muscle cell ( AHASMC ) , vitro , Investigators test hypothesis ACE inhibitor Ramipril , act antagonist Angiotensin II type 1 receptor ( ART1 ) stimulation reduce tissue Angiotensin II ( Ang II ) , impede mechanism Ang II stimulation ART1 exposure hypoxia enhance proliferation AHASMC production TGF-β1 collagen , via stimulation phosphoinositide-3-kinase signal suppression phosphatase tensin homologue , master regulator cell growth . If hypothesis correct , Aims # 1 # 2 demonstrate first time therapy Ramipril improve walk performance quality life claudicating PAD patient improve myopathy skeletal muscle ischemic low limb . The work Aim # 3 determine pathway hypoxia Angiotensin II cooperate induce myopathy ischemic muscle . Specific agent target pathway could become new treatment claudication advance stage PAD characterize leg rest pain gangrene .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>1 . A positive history chronic claudication , 2 . Exerciselimiting claudication establish history direct observation screen walk test administer evaluate vascular surgeon , 3 . Arterial occlusive disease per ankle Brachial index measurement and/or image modality , 4 . Stable blood pressure regimen , stable lipid regimen , stable diabetes regimen risk factor control 6 week . 1 . Rest pain tissue loss due PAD ( Fontaine stage III IV ) , 2. acute low extremity ischemic event secondary thromboembolic disease acute trauma , 3 . Walking capacity significantly limit condition claudication include leg ( joint/musculoskeletal , neurologic ) systemic ( heart , lung disease ) pathology , 4 . Current use either ACE inhibitor angiotensin II receptor blocker , 5 . Chronic kidney disease estimate Glomerular Filtration Rate &lt; 30 ml/min/1.73 m2 , 6 . History bilateral severe renal artery stenosis 7 ) History angioedema relate previous ACEinhibitor treatment know hypersensitivity ramipril ACE inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ramipril</keyword>
	<keyword>Angiotensin-converting enzyme</keyword>
	<keyword>Claudication</keyword>
	<keyword>Myopathy</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
</DOC>